-
How to assess the clinical benefit of anticancer drug therapy regimens and allocate the budget?
DOI 10.31917/2503191
N.M. Volkov
-
Immunotherapy of gastrointestinal malignancies (gastroesophageal and colorectal carcinoma)
DOI 10.31917/2503196
А.А. Tryakin, М.Yu. Fedyanin, I.А. Pokataev, О.А. Kuznetsova, О.В. Bzhadug
-
Immunotherapy in the treatment of urological tumors
DOI 10.31917/2503223
S.A. Reva, V.D. Yakovlev, A.V. Arnautov, K.A. Nikulina, B.P. Sergey
-
Targeted therapy for breast cancer
DOI 10.31917/2503241
M.A. Frolova, M.B. Stenina
-
Innovative regimens in the therapy of NSCLC
DOI 10.31917/2503265
F.V. Moiseenko
-
Alkalization therapy in cancer treatment
DOI 10.31917/2503272
A.A. Bogdanov, An.A. Bogdanov, V.M. Moiseyenko
-
Personalisation of antitumour drug therapy of disseminated gastric cancer within the framework of molecular classification
DOI 10.31917/2503281
D.P. Guzhavin, G.G. Makiev, R.Sh. Abdulaeva, E.S. Obarevich, I.A. Vaniev, O.A. Kuznetsova, D.A. Gavrilova, A.A. Tryakin
-
Extragonadal germinogenic tumor of the mediastinum. A clinical case
DOI 10.31917/2503295
I.N. Roshchin, P.V. Nesterov, O.A. Bartenyeva, A.V. Ukharsky